Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report

[1] Falk RH(1997)The systemic amyloidosis N Engl J Med 337 898-909

[2] Comezo RL(2009)Susceptibility to AA amyloidosis in rheumatic disease: a critical overview Arthritis Rheum 61 1435-1440

[3] Skinner M(2011)Amyloid a amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment Clin Exp Rheumatol 29 850-857

[4] Obici L(2014)Therapeutic benefits of tocilizumab vary in different organs of a patient with AA amyloidosis Case Rep Nephrol 2014 823093-409

[5] Raimondi S(2014)Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis Mod Rheumatology 24 405-1197

[6] Lavetelli F(2010)Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis Clin Rheumatol 29 1195-640

[7] Bellotti V(2016)Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases Pediatr Nephrol 31 633-234

[8] Merlini G(1985)Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal Nephron 40 232-201

[9] Nakamura T(1983)Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature Hum Pathol 14 195-74

[10] Matsui M(2014)Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature CEN Case Rep 3 68-1741

[1] Falk RH(1997)The systemic amyloidosis N Engl J Med 337 898-909

[2] Comezo RL(2009)Susceptibility to AA amyloidosis in rheumatic disease: a critical overview Arthritis Rheum 61 1435-1440

[3] Skinner M(2011)Amyloid a amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment Clin Exp Rheumatol 29 850-857

[4] Obici L(2014)Therapeutic benefits of tocilizumab vary in different organs of a patient with AA amyloidosis Case Rep Nephrol 2014 823093-409

[5] Raimondi S(2014)Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis Mod Rheumatology 24 405-1197

[6] Lavetelli F(2010)Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis Clin Rheumatol 29 1195-640

[7] Bellotti V(2016)Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases Pediatr Nephrol 31 633-234

[8] Merlini G(1985)Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal Nephron 40 232-201

[9] Nakamura T(1983)Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature Hum Pathol 14 195-74

[10] Matsui M(2014)Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature CEN Case Rep 3 68-1741